TrialJournal of gynecologic oncology2025

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.

Shin Nishio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.